摘要
目的:良性前列腺增生(BPH)是一种临床进展性疾病,本研究观察了富半胱氨酸61(CYR61)、血管内皮生长因子-C(VEGF-C)、IL-6、细胞色素C(cytochrome c)、凋亡蛋白caspase-3及细胞核增殖指数Ki-67在BPH组织中的表达,并分析与BPH临床进展危险因素之间的相关性,探讨预测BPH临床进展的分子标志物。方法:收集BPH患者前列腺标本288例,记录所有患者的年龄、前列腺体积、血清PSA水平及国际前列腺症状评分(IPSS)。明确前列腺组织中BPH病理学改变后将所有标本制作为BPH组织芯片。采用免疫组化ABC法对CYR61、VEGF-C、IL-6、cytochrome c、caspase-3和Ki-67的表达水平进行检测,并对不同分子标记物与BPH临床进展危险因素之间的相关性进行分析。利用免疫荧光双染技术检测BPH组织中CYR61和VEGF-C的同步表达和定位。结果:288例BPH标本中CYR61、VEGF-C、IL-6、cytochrome c、caspase-3和Ki-67的阳性表达例数分别为198例、221例、135例、76例、109例和102例,其阳性表达率分别为68.8%、76.7%、46.9%、26.4%、37.8%和35.4%。CYR61和VEGF-C表达与患者年龄、前列腺体积、血清PSA水平呈正相关(P<0.05)。cytochrome c和caspase-3表达与前列腺体积呈负相关(P<0.05)。CYR61和VEGF-C的免疫荧光双染结果证实了BPH组织中CYR61和VEGF-C的同步表达。结论:CYR61和VEGF-C的高表达对BPH的临床进展可能具有预测作用。
Objective:The pathogenesis and development of benign prostatic hyperplasia(BPH)have been widely studied.This study aimed to investigate the possible role of CYR61,vascular endothelial growth factor-C(VEGF-C),interleukin-6(IL-6),cytochrome c,caspase-3 and Ki-67 in the clinical progression of BPH.Method:All tissue specimens from 288 BPH cases who underwent transurethral resection of the prostate(TURP)were processed and transferred to tissue microarrays.Patients’age,prostate volume,serum prostate specific antigen(PSA)level and international prostate symptom score(IPSS)of BPH cases were collected before surgery.The expression of CYR61,VEGF-C,IL-6,cytochrome c,caspase-3 and Ki-67 were examined by immunohistologic ABC method in BPH specimens,and possible correlation between different biomarkers and the risk factors of BPH clinical progression was also analyzed.The co-localization of CYR61 with VEGF-C protein was observed by double-label immunofluorescence.Result:The positive expression of CYR61,VEGF-C,IL-6,cytochrome c,caspase-3 and Ki-67 in BPH cases were 68.8%(198/288),76.7%(221/288),46.9%(135/288),26.4%(76/288),37.8%(109/288)and 35.4%(102/288),respectively.The expression of both CYR61 and VEGF-C were positively correlated with patients’age,prostate volume,serum PSA level(P<0.05).Furthermore,cytochrome c and caspase-3 expression were negatively correlated with prostate volume(P<0.05).Double-label immunoflurescence staining revealed the co-localization of CYR61 and VEGF-C in BPH tissues,especially in BPH stromal cells.Conclusion:CYR61 and VEGF-C expression may serve as biomarkers for the prediction of BPH clinical progression.
作者
马丁
任瑞民
尚吉文
程伟
张雁钢
MA Ding;REN Ruimin;SHANG Jiwen;CHENG Wei;ZHANG Yangang(Department of Urology,Shanxi Dayi Hospital,Shanxi Academy of Medical Sciences,Taiyuan,030031,China)
出处
《临床泌尿外科杂志》
2019年第6期444-448,共5页
Journal of Clinical Urology
